Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company tdeveloping cancer therapies. The company's product pipeline Etrumadenant, Zimberelimab, and Domvanalimab, the latter of which targets first-line metastatic non-small cell lung cancer. Arcus Biosciences was incorporated in 2015 and is headquartered in Hayward, CA.
Name / Ticker | Price | Zen Rating |
---|---|---|
$7.77 | A | |
$22.48 | A | |
$40.37 | A |